Join the 'Sargramostim' group to help and get support from people like you.
Posted 4 Nov 2014 by Drugs.com
TUESDAY, Nov. 4, 2014 – Patients with advanced melanoma may live longer when treated with a combination of the cancer drug Yervoy and the immune system booster sargramostim, a new study finds. Patients given the two drugs had a median survival of 17.5 months, compared to 12.7 months for those on Yervoy (ipilimumab) alone. At one year, overall survival was nearly 69 percent for those on the combination therapy, versus 53 percent for those on Yervoy alone, the researchers said. "Patients did live longer, as well as having less serious side effects, when given the combination," said lead researcher Dr. F. Stephen Hodi, an assistant professor of medicine at the Dana-Farber Cancer Institute in Boston. Melanoma is the most serious form of skin cancer. In the United States, more than 12,000 people die from advanced melanoma each year, the U.S. Centers for Disease Control and Prevention ... Read more